Stealth BioTherapeutics (MITO) announced the pricing of initial public offering of 6.5 million American Depositary Shares or ADSs at $12.00 per ADS, the lower end of the expected range of between $12 and $14 per ADS. The offering is expected to close on February 20, 2019.
Stealth stated that its...
Avedro Inc. (AVDR, a commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, said that it priced its initial public offering of 5 million shares of common stock at a price to the public...
TCR2 Therapeutics Inc. (TCRR) said that it priced its initial public offering of 5 million shares of common stock at a public offering price of $15.00 per share, for aggregate gross proceeds of $75.0 million, before deducting underwriting discounts and commissions and offering expenses.
The company...
Levi Strauss & Co. said that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not...
The founders of Lyft Inc. plan to take near-majority voting control of the ride-hailing company when it goes public this year, the Wall Street Journal reported Tuesday, citing people familiar with the matter.
Lyft's founders John Zimmer and Logan Green are working with underwriters and lawyers on...
Anchiano Therapeutics, formerly known as Biocancell, is a clinical-stage biotechnology company developing a targeted gene therapy to improve the standard treatment for early-stage bladder cancer.
Harpoon Therapeutics, Inc. is a clinical-stage an immuno-oncology company, and its proprietary antibody-based drug discovery platform is called TriTAC, which offers a new way to unleash the target cell-killing properties of a patient's own immune system.